Vertex and NHS reach agreement for “Landmark” CF therapy deal

Vertex has achieved an agreement with NHS England to reimburse its triple combination therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor), should the medicine win European approval. The new expanded agreement includes reimbursed access to Vertex’ currently licensed medicines – Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor), as well as the triple combination therapy if

Continue Reading

NHS England confirms 4 new integrated care systems

NHS England has confirmed four new integrated care systems (ICS) in England, joining the 14 already in existence plus two devolved health systems in Greater Manchester and Surrey. The action leads to around half of England’s population now being served by such a system, including the whole of Yorkshire (with the confirmation of an ICS

Continue Reading